INCY...broke out. Actually yesterday. Good follow through today without any news. ;)
latest presentation:
http://library.corporate-ir.net/library/69/697/69764/items/271301/Piper_2007_11_26_2007.pdf
nice insider buying:
>:D
Incyte novel JAK Inhibitor INCB18424 shows positive results in Phase I/II trial
Monday , December 10, 2007 17:23ET
By Staff Reporter
NEW YORK, Dec 11, 2007 (Thomson Financial via COMTEX) -- Incyte Corp. Monday said data from a Phase I/II trial of INCB18424, the company's orally-available janus-associated kinase inhibitor, demonstrates that it provides rapid and profound clinical benefits in myelofibrosis patients.
Myelofibrosis is a neoplastic condition with a survival rate of three to seven years, characterized by varying degrees of bone marrow failure, life-threatening splenic enlargement, and marked constitutional symptoms.
Results presented involved 11 of the patients in the study, and showed that mean reduction in spleen size reached 52% in the first month and 86% in the third, the company said. Additionally, all six patients treated for longer than three months achieved clinical improvement as defined by the International Working Group.
Incyte also said that INCB18424 was well-tolerated and that no patients discontinued the study.
INCY: Short Interest UP 0.7% to 10.0M at the End of Nov 2007
Tuesday , December 11, 2007 16:18ET
According to new short interest data from NASDAQ, short interest for Incyte Corporation (NasdaqNM: INCY) INCREASED 0.7% to 10,001,640 shares as reported at month-end November, 2007.
SYMBOL MID NOVEMBER END NOVEMBER CHANGE CHANGE DAYS/COVER
-------- ------------- ------------- ------------- ------------ ----------
INCY 9,930,813 10,001,640 +70,827 +0.71% 11
Based on INCY's 20-day average daily share volume of 977,705, it would require approximately 11 day(s) of buying to cover this short interest.
nice sum up of baker brother investment:
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5333206
nice chart also, anybody invested also?
Incyte Announces $8.5 million Gain from Sale of Investment
Friday December 21, 7:30 am ET
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation today announced the receipt of approximately $8.5 million as a result of the sale of Velocity11, a privately-held life sciences technology company in which Incyte held an ownership position. Incyte may receive additional consideration of approximately $900,000 after a one year escrow period. As a result of the sale, Incyte will record a gain of approximately $8.5 million in the fourth quarter of 2007
fyi
short update:
INCY: Short Interest UP 0.5% to 10.1M in Mid Dec 2007
Wednesday, December 26, 2007 16:18ET
According to new short interest data from NASDAQ, short interest for Incyte Corporation (NasdaqNM: INCY) INCREASED 0.5% to 10,056,591 shares as reported in mid-December, 2007.
Based on INCY's 20-day average daily share volume of 1,167,020, it would require approximately 9 day(s) of buying to cover this short interest.
chart:
fyi:
INCY: Jefferies Cuts to Hold from Buy; Sets Tgt @ $10; Analyst Notes
Friday , January 04, 2008 08:48ET
Issuer: Incyte Corporation (NasdaqNM: INCY)
Analyst Firm: Jefferies Group Inc.
Ratings Action: DOWNGRADE
Current Rating: Hold (from Buy)
Target Price: $10.00
Analyst Comments: While the firm maintains a favorable long-term outlook given its broad pipeline, the recent run-up in the share price upon promising, yet limited early clinical data for its JAK inhibitor (+40% in 4Q07 vs. down 4% for BTK; current EV ~$1B) sets us on the sidelines for a better entry point.
link:
http://www.knobias.com/research.pdf?id=12496